NextCure, Inc. (NASDAQ:NXTC) Short Interest Down 32.1% in November

NextCure, Inc. (NASDAQ:NXTC) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 44,900 shares, a decrease of 32.1% from the October 31st total of 66,100 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 43,000 shares, the days-to-cover ratio is presently 1.0 days.

NextCure Stock Performance

NASDAQ:NXTC remained flat at $1.17 on Friday. 12,594 shares of the company’s stock were exchanged, compared to its average volume of 65,145. The company has a 50 day moving average of $1.34 and a two-hundred day moving average of $1.47. NextCure has a 12-month low of $1.03 and a 12-month high of $2.57. The firm has a market capitalization of $32.77 million, a price-to-earnings ratio of -0.56 and a beta of 0.80.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their price target on shares of NextCure from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Monday, November 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NXTC. Armistice Capital LLC bought a new position in shares of NextCure in the second quarter worth $57,000. Geode Capital Management LLC lifted its holdings in NextCure by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after purchasing an additional 27,812 shares in the last quarter. Renaissance Technologies LLC boosted its stake in NextCure by 15.4% in the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after purchasing an additional 61,744 shares during the period. Vanguard Group Inc. grew its holdings in NextCure by 9.3% during the 1st quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after buying an additional 83,700 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in NextCure by 24.2% during the second quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock valued at $2,684,000 after acquiring an additional 328,918 shares in the last quarter. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.